Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, Kivitz AJ, Alvaro J, Nuki G, Furst DE, Herrero-Beaumont G, McInnes IB, Musikic P, Tak PP. van Holten J, et al. Among authors: tak pp. Ann Rheum Dis. 2005 Jan;64(1):64-9. doi: 10.1136/ard.2003.020347. Epub 2004 Jul 8. Ann Rheum Dis. 2005. PMID: 15242865 Free PMC article. Clinical Trial.
A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue.
van Kuijk AW, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, Zwinderman AH, Dijkmans BA, Tak PP. van Kuijk AW, et al. Among authors: tak pp. Ann Rheum Dis. 2009 Aug;68(8):1303-9. doi: 10.1136/ard.2008.091389. Epub 2008 Jul 22. Ann Rheum Dis. 2009. PMID: 18647851 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study.
Boumans MJ, Houbiers JG, Verschueren P, Ishikura H, Westhovens R, Brouwer E, Rojkovich B, Kelly S, den Adel M, Isaacs J, Jacobs H, Gomez-Reino J, Holtkamp GM, Hastings A, Gerlag DM, Tak PP. Boumans MJ, et al. Among authors: tak pp. Ann Rheum Dis. 2012 Feb;71(2):180-5. doi: 10.1136/annrheumdis-2011-200298. Epub 2011 Sep 14. Ann Rheum Dis. 2012. PMID: 21917822 Clinical Trial.
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, Bingham CO 3rd, Ashrafzadeh A, Travers H, Safa-Leathers S, Kumar S, Dummer W. Tak PP, et al. Arthritis Rheum. 2012 Feb;64(2):360-70. doi: 10.1002/art.33353. Arthritis Rheum. 2012. PMID: 22389919 Free article. Clinical Trial.
Activation of the STAT1 pathway in rheumatoid arthritis.
Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP, Verweij CL. Kasperkovitz PV, et al. Among authors: tak pp. Ann Rheum Dis. 2004 Mar;63(3):233-9. doi: 10.1136/ard.2003.013276. Ann Rheum Dis. 2004. PMID: 14962955 Free PMC article.
600 results